---
title: "Expected to open the first BNCT Boron Neutron Capture Therapy Center in Hong Kong, China Life Science is eager to settle in the Hong Kong-Shenzhen Innovation Park"
description: "China Medical Service and Hong Kong-Shenzhen Science and Technology Innovation Park Company have signed a memorandum of understanding to jointly build the BNCT Boron Neutron Capture Therapy Center in "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/202302692.md"
published_at: "2024-04-19T00:12:04.000Z"
---

# Expected to open the first BNCT Boron Neutron Capture Therapy Center in Hong Kong, China Life Science is eager to settle in the Hong Kong-Shenzhen Innovation Park

> China Medical Service and Hong Kong-Shenzhen Science and Technology Innovation Park Company have signed a memorandum of understanding to jointly build the BNCT Boron Neutron Capture Therapy Center in the Hetao area of Hong Kong. This marks China Medical Service as the first enterprise in Hong Kong to establish a Boron Neutron Capture Therapy Center, laying the foundation for serving cancer patients in Hong Kong and the surrounding areas in the future

On April 18, China Biotech Services (08037) announced that it had signed a memorandum of understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited (hereinafter referred to as "Hong Kong-Shenzhen Sci-Tech Park") and held a partnership launch ceremony at the Hong Kong-Shenzhen Sci-Tech Park.

According to the memorandum of understanding, Hong Kong-Shenzhen Sci-Tech Park plans to introduce the Boron Neutron Capture Therapy (BNCT) project. China Biotech Services will collaborate with Japan's Sumitomo Heavy Industries Machinery Co., Ltd. and Japanese boron drug company Stella Pharma Co., Ltd. to jointly build the BNCT Hetao Treatment Center in the Hetao area of Hong Kong.

Hong Kong-Shenzhen Sci-Tech Park is the Hong Kong area of the Hetao Hong Kong-Shenzhen Science and Technology Innovation Cooperation Zone. With its geographical advantages, it will become an important platform for cooperation with mainland China in science and technology innovation, helping to promote Hong Kong's integration into national development and benefiting partners of Hong Kong-Shenzhen Sci-Tech Park and the entire innovation community. The introduction of the Boron Neutron Capture Therapy project this time also reflects Hong Kong-Shenzhen Sci-Tech Park's optimism about the development prospects of this therapy.

According to the Securities Times app, China Biotech Services is steadily advancing its CAR-T business and the commercialization of the Boron Neutron Treatment Center as expected. The Pengbo Boron Neutron Hospital located in the Boao Lecheng International Medical Tourism Pioneer Zone has achieved full completion as planned in December 2023 and has begun installing equipment. It is expected to start operations and receive patients by the end of 2024 or early 2025.

The memorandum of understanding reached with Hong Kong-Shenzhen Sci-Tech Park Company signifies the specific manifestation of its accelerated commercialization process of the Boron Neutron Capture Therapy, marking China Biotech Services as the first enterprise to establish a Boron Neutron Capture Treatment Center in Hong Kong. This will lay the foundation for its future to serve cancer patients in Hong Kong, the Greater Bay Area, Southeast Asia, and South Asia based on its geographical advantages.

Meanwhile, China Biotech Services' subsidiary, Shanghai Longyao Biotechnology, is conducting clinical trials at Shanghai Ruijin Hospital and Jiangsu Provincial People's Hospital, and will announce the latest clinical research data on the targeted CD20 CAR-T product LY007 cell injection solution at the 2024 ASCO Annual Meeting.

In recent years, China Biotech Services has been committed to building an advanced biotechnology platform for integrated cancer diagnosis and treatment, with a focus on precision diagnosis, CAR-T cell therapy, and BNCT Boron Neutron Therapy. The company has already achieved regional or international leading advantages. With the accelerated development of the company's CAR-T business and the rapid commercialization of Boron Neutron Therapy, China Biotech Services is poised for a moment of value explosion

### Related Stocks

- [08037.HK - CH BIOTECH SER](https://longbridge.com/en/quote/08037.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 领土问题首上谈判桌 俄乌博弈进入 “深水区” | 在日内瓦举行的俄美乌三方谈判中，领土问题首次被纳入讨论议程。谈判于 2 月 17 日至 18 日进行，俄方称谈判 “务实高效”，乌方表示讨论深入且具有实质意义，美方则称各方同意继续谈判。尽管各方均表示取得进展，但关于下一轮谈判的细节尚未公布 | [Link](https://longbridge.com/en/news/276289464.md) |
| “有组织控制了全球三分之一的超级油轮” | 韩国 Sinokor 集团已控制约 120 艘超大型油轮，占可用船队近三分之一，规模前所未见。背后浮现地中海航运创始人 Gianluigi Aponte 身影。这场收购引发市场恐慌，运费创 30 多年来最强开局。油轮订单随之增至十年新高。 | [Link](https://longbridge.com/en/news/276059635.md) |
| 奥洛兹美医疗｜8-K：2025 财年营收 13.97 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276167416.md) |
| 卡比海运｜10-K：2025 财年营收 33.64 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276153597.md) |
| 港股异动：中国智慧能源涨 16.42%，资金流向明显，市场情绪引发波动性关注 | 中国智慧能源涨 16.42%；华润电力跌 0.44%，成交额达到 89.5 百万港币；中广核电力涨 1.28%，成交额达到 77.47 百万港币；龙源电力涨 0.14%，成交额达到 41.14 百万港币；华能国际电力股份跌 0.90%，市值 | [Link](https://longbridge.com/en/news/276421566.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.